Recursion Pharmaceuticals, Inc. Class A RXRX 深 沪
等待开盘 10-07 09:30:00 美东时间
4.5579
-0.222
-4.65%
华盛通- 最 高5.19
- 今 开4.80
- 成交量 5317.33万股
- 最 低 3.10
- 昨 收 4.78
- 总市值 78.40万
- 52周最高 7.18
- 市盈率 静 --
- 换手率 30914.73%
- 52周最低 2.77
- 委 比 27.70%
- 总股本 0.00亿
- 历史最高 42.81
- 量 比 2.98
- 振 幅 43.72%
- 历史最低 1.10
- 每 手 1
- 风险率 0.83%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多'HHS launches project to speed up clinical trials' - Axios
https://www.axios.com/2026/09/30/hhs-clinical-trials-redesign
10-01 03:17
Squeeze Watch: 10 Stocks With Over 33% Short Interest
Ten stocks have over 34% of their float short, with ONDS and BROS on the list led by VG.
09-26 02:00
Citeline Announces Expanded Strategic Partnership With Recursion, Advancing AI-Enabled ClinTech Platform
Citeline, a leader in clinical solutions for the life sciences industry, today announced an expanded strategic partnership with Recursion (NASDAQ:RXRX), a leading tech-bio company decoding biology through advanced data
03-31 21:05
ARK Unplugged: How Cathie Wood Crushed the S&P 500 in 2025
ARK's 2025 winners included Robinhood, AMD and Palantir, while its losers were The Trade Desk, Recursion and Twist.
02-25 04:52
Recursion Pharmaceuticals's Earnings Outlook
Recursion Pharmaceuticals (NASDAQ:RXRX) is set to give its latest quarterly ear...
02-25 03:02
Nvidia, Joby, CoreWeave, Lucid and More Stocks with Earnings This Week
Here's a look at the earnings calendar for the week ahead, including reports from Nvidia, Joby, CoreWeave, Salesforce, Lucid and more.
02-23 23:33
3 Small AI Plays to Buy for 2026
Wall Street ends 2026 positively with tech stocks dominating, but concerns over valuations drive interest in smaller AI stocks for 2026.
2025-12-27 02:28
Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why
Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10.
2025-12-18 02:06
Why Are Shares Of Recursion Pharmaceuticals Higher Today?
Shares of Recursion Pharmaceuticals are trading higher Monday after the company reported positive data from an ongoing trial.
2025-12-08 23:48
Jim Cramer: This Health Care Stock Has Been 'Horrendous'
Jim Cramer doesn't recommend Recursion Pharmaceuticals (NASDAQ: RXRX) due to weak earnings and CEO transition. Stock has mixed technicals and death cross.
2025-12-05 21:19
